(Q36057877)

11 August 2017

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia (English)

1 reference

11 August 2017

1 reference

1 reference

5

Ann-Kathrin Eisfeld

1 reference

11 August 2017

23

Guido Marcucci

1 reference

11 August 2017

19

Clara D Bloomfield

1 reference

11 August 2017

9

John C Byrd

1 reference

11 August 2017

20

Michael A Caligiuri

1 reference

11 August 2017

12

John P Curfman

1 reference

11 August 2017

4

Susan Geyer

1 reference

11 August 2017

8

Rebecca Klisovic

1 reference

11 August 2017

21

Michael R Grever

1 reference

11 August 2017

22

Ramiro Garzon

1 reference

11 August 2017

1

William Blum

1 reference

11 August 2017

13

Steven M Devine

1 reference

11 August 2017

2

Sebastian Schwind

1 reference

11 August 2017

16

Cheryl Kefauver

1 reference

11 August 2017

10

Ramasamy Santhanam

1 reference

11 August 2017

17

Danilo Perrotti

1 reference

11 August 2017

Somayeh S Tarighat

3

1 reference

11 August 2017

Susan Whitman

6

1 reference

11 August 2017

Alison Walker

7

1 reference

11 August 2017

Hongyan Wang

11

1 reference

11 August 2017

Samson Jacob

14

1 reference

11 August 2017

Celia Garr

15

1 reference

11 August 2017

Kenneth K Chan

18

1 reference

11 August 2017

language of work or name

English

0 references

publication date

7 May 2012

1 reference

11 August 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

Blood

1 reference

11 August 2017

119

1 reference

11 August 2017

25

1 reference

11 August 2017

6025-6031

1 reference

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383015

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383015

Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383015

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383015

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383015

FLT3 inhibition as a targeted therapy for acute myeloid leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383015

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383015

Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383015

MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383015

Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383015

Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383015

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383015

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383015

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383015

Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383015

Phase I study of bortezomib in refractory or relapsed acute leukemias

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383015

Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3383015

Prognostic index for adult patients with acute myeloid leukemia in first relapse

23 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22566605

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1182/BLOOD-2012-03-413898

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

22566605

1 reference